Nascent Biotech Inc
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing Multi… Read more
Nascent Biotech Inc (NBIO) - Total Liabilities
Latest total liabilities as of June 2024: $741.93K USD
Based on the latest financial reports, Nascent Biotech Inc (NBIO) has total liabilities worth $741.93K USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nascent Biotech Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how Nascent Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Nascent Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Nascent Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Feel Foods Ltd
PINK:FLLLF
|
USA | $1.27 Million |
|
Boratr Co. Ltd.
KO:250000
|
Korea | ₩49.18 Billion |
|
Financial 15 Split Corp
PINK:FNNCF
|
USA | $621.30 Million |
|
VERASTEM (2VS.SG)
STU:2VS
|
Germany | €65.74 Million |
|
Big Tech 50 R&D-Limited Partnership
TA:BIGT
|
Israel | ILA1.62 Million |
|
Arogo Capital Acquisition Corp. Warrant
NASDAQ:AOGOW
|
USA | $9.15 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Nascent Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nascent Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nascent Biotech Inc (2014–2024)
The table below shows the annual total liabilities of Nascent Biotech Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-03-31 | $808.79K | -47.86% |
| 2023-03-31 | $1.55 Million | +99.66% |
| 2022-03-31 | $776.89K | -36.53% |
| 2021-03-31 | $1.22 Million | -57.49% |
| 2020-03-31 | $2.88 Million | +369.16% |
| 2019-03-31 | $613.64K | +201.73% |
| 2018-03-31 | $203.37K | +22.51% |
| 2017-03-31 | $166.00K | -94.41% |
| 2016-03-31 | $2.97 Million | -5.55% |
| 2015-03-31 | $3.14 Million | +100.91% |
| 2014-03-31 | $1.57 Million | -- |